Gene symbol   |
Time course plot |
Accession |
Description |
Treatment |
15min |
30min |
1hr |
2hr |
4hr |
8hr |
20hr |
14927508 3 |  |
149275083 |
Unknown |
KLA | .74 |
.68 |
.68 |
.77 |
.71 |
.85 |
.69 |
| ATP | .85 |
.69 |
1.26 |
.89 |
.89 |
1.26 |
.64 |
| KLA/ATP | .64 |
.63 |
1.07 |
.96 |
1.39 |
1.07 |
.82 |
|
1500003O 03Rik |  |
NM_019769 |
RIKEN cDNA 1500003O03 gene (1500003O03Rik), mRNA [NM_019769] |
KLA | .92 |
.89 |
.89 |
.86 |
.85 |
.92 |
1.08 |
| ATP | 1.01 |
1.16 |
1.16 |
1.53 |
1.70 |
3.33 |
2.09 |
| KLA/ATP | .89 |
.97 |
.93 |
1.17 |
1.19 |
2.86 |
2.57 |
|
2010110P 09Rik |  |
NM_027363 |
RIKEN cDNA 2010110P09 gene (2010110P09Rik), mRNA [NM_027363] |
KLA | .99 |
.98 |
1.02 |
.99 |
.94 |
1.01 |
1.01 |
| ATP | 1.04 |
1.05 |
.97 |
1.05 |
.95 |
.98 |
.95 |
| KLA/ATP | .93 |
1.00 |
1.02 |
.97 |
1.01 |
.96 |
.97 |
|
AK036998
|  |
AK036998 |
adult female vagina cDNA, RIKEN full-length enriched library, clone:9930034M05 product:unclassifiable, full insert sequence. [AK036998] |
KLA | 1.43 |
1.09 |
.89 |
.79 |
.96 |
.97 |
.71 |
| ATP | 1.04 |
1.04 |
.71 |
.64 |
.90 |
.82 |
.82 |
| KLA/ATP | 1.34 |
1.23 |
1.01 |
.89 |
1.10 |
.82 |
.75 |
|
Araf |  |
NM_009703 |
v-raf murine sarcoma 3611 viral oncogene homolog (Araf), mRNA [NM_009703] |
KLA | .87 |
.80 |
.89 |
.93 |
1.10 |
1.19 |
1.16 |
| ATP | 1.09 |
1.11 |
1.19 |
1.18 |
.78 |
.53 |
1.18 |
| KLA/ATP | 1.00 |
.95 |
.99 |
.93 |
.63 |
.55 |
1.27 |
|
BB113440
|  |
BB113440 |
gb|BB113440 RIKEN full-length enriched, adult male urinary bladder Mus musculus cDNA clone 9530041B19 3. [BB113440] |
KLA | .94 |
.95 |
.94 |
.95 |
1.05 |
.99 |
1.05 |
| ATP | 1.03 |
1.07 |
1.79 |
1.71 |
1.51 |
1.12 |
1.06 |
| KLA/ATP | .95 |
1.11 |
1.27 |
1.15 |
1.05 |
1.14 |
1.25 |
|
Bid |  |
NM_007544 |
BH3 interacting domain death agonist (Bid), mRNA [NM_007544] |
KLA | 1.03 |
1.08 |
1.09 |
1.14 |
1.01 |
.99 |
.68 |
| ATP | 1.06 |
1.11 |
.97 |
.89 |
1.04 |
1.17 |
1.08 |
| KLA/ATP | .88 |
1.09 |
.92 |
1.06 |
1.16 |
1.28 |
1.56 |
|
Braf |  |
NM_139294 |
Braf transforming gene (Braf), mRNA [NM_139294] |
KLA | 1.52 |
1.57 |
1.55 |
1.33 |
1.83 |
1.52 |
1.60 |
| ATP | 1.08 |
1.17 |
1.02 |
1.37 |
.95 |
1.15 |
.95 |
| KLA/ATP | 1.64 |
1.69 |
1.39 |
1.51 |
1.04 |
1.31 |
1.26 |
|
Casp3 |  |
NM_009810 |
caspase 3 (Casp3), mRNA [NM_009810] |
KLA | 1.66 |
1.94 |
2.47 |
2.61 |
3.01 |
2.96 |
1.44 |
| ATP | .90 |
.99 |
1.17 |
1.30 |
1.01 |
1.17 |
.86 |
| KLA/ATP | 1.55 |
1.87 |
2.40 |
2.35 |
2.27 |
2.84 |
2.52 |
|
Casp3 |  |
U49929 |
ICE-like cysteine protease (Lice) mRNA, complete cds. [U49929] |
KLA | 1.71 |
1.87 |
2.69 |
3.11 |
3.64 |
3.42 |
1.52 |
| ATP | 1.04 |
1.07 |
1.16 |
1.34 |
.98 |
1.27 |
.86 |
| KLA/ATP | 1.80 |
1.96 |
2.46 |
2.91 |
2.50 |
3.24 |
3.10 |
|
Cd244 |  |
NM_018729 |
CD244 natural killer cell receptor 2B4 (Cd244), mRNA [NM_018729] |
KLA | 1.60 |
1.65 |
1.58 |
1.85 |
2.65 |
3.51 |
1.88 |
| ATP | .92 |
.93 |
1.03 |
.89 |
1.70 |
2.99 |
3.26 |
| KLA/ATP | 1.39 |
1.47 |
1.52 |
1.23 |
1.76 |
3.72 |
2.91 |
|
Cd247 |  |
AK016078 |
adult male testis cDNA, RIKEN full-length enriched library, clone:4930549J05 product:unclassifiable, full insert sequence. [AK016078] |
KLA | .95 |
1.01 |
.98 |
1.08 |
1.01 |
.95 |
.99 |
| ATP | 1.01 |
1.05 |
1.02 |
.99 |
1.02 |
1.01 |
1.07 |
| KLA/ATP | .97 |
.99 |
1.00 |
1.05 |
1.01 |
.96 |
.98 |
|
Cd247 |  |
NM_001113391 |
CD247 antigen (Cd247), transcript variant zeta, mRNA [NM_001113391] |
KLA | 3.06 |
3.63 |
3.61 |
2.90 |
3.04 |
1.93 |
1.28 |
| ATP | 1.07 |
1.03 |
1.19 |
1.21 |
1.39 |
1.42 |
1.12 |
| KLA/ATP | 3.09 |
3.74 |
2.98 |
2.90 |
2.14 |
2.13 |
2.41 |
|
Cd247 |  |
NM_031162 |
CD247 antigen (Cd247), transcript variant eta, mRNA [NM_031162] |
KLA | 1.29 |
1.35 |
1.39 |
1.26 |
1.35 |
1.16 |
1.17 |
| ATP | .99 |
1.01 |
1.04 |
1.03 |
1.08 |
1.05 |
1.02 |
| KLA/ATP | 1.34 |
1.42 |
1.24 |
1.33 |
1.18 |
1.18 |
1.23 |
|
Cd48 |  |
NM_007649 |
CD48 antigen (Cd48), mRNA [NM_007649] |
KLA | 1.35 |
1.36 |
1.64 |
1.57 |
1.80 |
1.74 |
1.59 |
| ATP | 1.16 |
1.09 |
1.13 |
1.12 |
.93 |
.49 |
1.24 |
| KLA/ATP | 1.49 |
1.50 |
1.72 |
1.57 |
1.55 |
1.04 |
1.52 |
|
Csf2 |  |
NM_009969 |
colony stimulating factor 2 (granulocyte-macrophage) (Csf2), mRNA [NM_009969] |
KLA | 1.44 |
1.53 |
1.38 |
1.37 |
1.15 |
1.21 |
1.14 |
| ATP | 1.01 |
1.02 |
1.85 |
9.73 |
2.64 |
1.90 |
1.14 |
| KLA/ATP | 1.49 |
1.84 |
2.14 |
2.80 |
1.67 |
1.36 |
1.35 |
|
EG629860
|  |
M17953 |
gb|Mouse Ig rearranged H-chain V-region mRNA VJ1 [M17953] |
KLA | .96 |
1.05 |
1.03 |
1.08 |
1.08 |
1.02 |
.98 |
| ATP | .97 |
.99 |
1.05 |
1.10 |
.95 |
.94 |
.91 |
| KLA/ATP | .96 |
.94 |
.97 |
1.04 |
.97 |
1.01 |
.89 |
|
Fas |  |
AK086933 |
0 day neonate lung cDNA, RIKEN full-length enriched library, clone:E030012O08 product:tumor necrosis factor receptor superfamily, member 6, full insert sequence. [AK086933] |
KLA | 6.31 |
6.56 |
6.33 |
6.70 |
4.93 |
3.74 |
2.48 |
| ATP | .95 |
1.04 |
1.33 |
1.55 |
1.85 |
6.00 |
2.77 |
| KLA/ATP | 5.67 |
7.16 |
7.71 |
7.73 |
6.02 |
5.79 |
7.85 |
|
Fas |  |
NM_007987 |
Fas (TNF receptor superfamily member 6) (Fas), mRNA [NM_007987] |
KLA | 17.08 |
17.45 |
19.08 |
17.38 |
13.33 |
6.78 |
4.46 |
| ATP | .98 |
.96 |
1.64 |
3.05 |
5.58 |
12.91 |
1.89 |
| KLA/ATP | 16.57 |
17.25 |
26.06 |
23.57 |
22.03 |
16.74 |
13.29 |
|
Fasl |  |
NM_010177 |
Fas ligand (TNF superfamily, member 6) (Fasl), mRNA [NM_010177] |
KLA | 1.03 |
1.01 |
1.03 |
1.02 |
1.01 |
1.01 |
1.00 |
| ATP | 1.00 |
.99 |
1.04 |
1.21 |
1.18 |
1.20 |
1.01 |
| KLA/ATP | 1.00 |
1.02 |
1.07 |
1.16 |
1.18 |
1.23 |
1.00 |
|
Fcer1g |  |
J05020 |
gb|Mouse mast cell high affinity IgE receptor (Fc-epsilon-RI) gamma subunit mRNA, complete cds. [J05020] |
KLA | 1.41 |
1.43 |
1.53 |
1.61 |
1.91 |
2.07 |
2.49 |
| ATP | 1.13 |
1.21 |
.88 |
1.25 |
1.06 |
.92 |
1.45 |
| KLA/ATP | 1.64 |
1.64 |
1.25 |
1.84 |
1.45 |
1.39 |
2.32 |
|
Fcer1g |  |
NM_010185 |
Fc receptor, IgE, high affinity I, gamma polypeptide (Fcer1g), mRNA [NM_010185] |
KLA | 1.49 |
1.54 |
1.48 |
1.62 |
2.18 |
2.06 |
2.35 |
| ATP | 1.10 |
1.16 |
.78 |
1.00 |
.90 |
.98 |
1.18 |
| KLA/ATP | 1.48 |
1.67 |
1.26 |
1.71 |
1.33 |
1.40 |
2.13 |
|
Fcgr4 |  |
NM_144559 |
Fc receptor, IgG, low affinity IV (Fcgr4), mRNA [NM_144559] |
KLA | 9.03 |
8.68 |
9.82 |
11.51 |
11.12 |
13.01 |
7.95 |
| ATP | 1.04 |
.95 |
1.22 |
1.43 |
1.17 |
2.80 |
4.48 |
| KLA/ATP | 8.63 |
8.84 |
11.99 |
11.84 |
12.40 |
13.56 |
12.31 |
|
Fyn |  |
U70324 |
Fyn(T) (L-fyn(T)) mRNA, complete cds. [U70324] |
KLA | 1.23 |
1.27 |
1.31 |
1.27 |
1.31 |
.87 |
.48 |
| ATP | .88 |
.71 |
.66 |
.75 |
.90 |
1.28 |
.51 |
| KLA/ATP | 1.12 |
1.01 |
.94 |
.84 |
1.25 |
1.51 |
.53 |
|
Grb2 |  |
NM_008163 |
growth factor receptor bound protein 2 (Grb2), mRNA [NM_008163] |
KLA | .92 |
.88 |
.90 |
1.27 |
1.43 |
1.22 |
1.00 |
| ATP | 1.02 |
.83 |
.51 |
.42 |
.92 |
.70 |
.57 |
| KLA/ATP | .84 |
.77 |
.61 |
.56 |
1.56 |
1.49 |
.52 |
|
Grb2 |  |
U07617 |
Grb2 adaptor protein (grb2) mRNA, complete cds. [U07617] |
KLA | .83 |
.80 |
.95 |
1.13 |
1.38 |
1.36 |
1.06 |
| ATP | .84 |
.74 |
.51 |
.41 |
.82 |
.74 |
.59 |
| KLA/ATP | .77 |
.70 |
.57 |
.54 |
1.49 |
1.39 |
.53 |
|
Gzmb |  |
NM_013542 |
granzyme B (Gzmb), mRNA [NM_013542] |
KLA | 1.03 |
.96 |
1.07 |
1.10 |
1.04 |
.98 |
1.07 |
| ATP | .90 |
1.05 |
1.02 |
.98 |
.90 |
1.09 |
1.02 |
| KLA/ATP | .96 |
.98 |
1.20 |
1.17 |
1.03 |
1.06 |
1.07 |
|
H2-Bl |  |
NM_008199 |
histocompatibility 2, blastocyst (H2-Bl), mRNA [NM_008199] |
KLA | 1.29 |
1.32 |
1.40 |
1.28 |
1.36 |
1.46 |
1.80 |
| ATP | 1.04 |
1.11 |
1.02 |
1.34 |
1.28 |
1.32 |
1.47 |
| KLA/ATP | 1.32 |
1.39 |
1.34 |
1.77 |
1.41 |
1.61 |
2.39 |
|
H2-D1 |  |
AK169750 |
2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:E430019E13 product:histocompatibility 2, D region locus 1, full insert sequence [AK169750] |
KLA | .99 |
.98 |
.96 |
.99 |
.93 |
.91 |
.94 |
| ATP | .96 |
1.01 |
1.02 |
.95 |
1.05 |
1.00 |
.98 |
| KLA/ATP | .92 |
.94 |
.97 |
.97 |
.98 |
.92 |
1.03 |
|
H2-D1 |  |
NM_010380 |
histocompatibility 2, D region locus 1 (H2-D1), mRNA [NM_010380] |
KLA | 1.38 |
1.45 |
1.73 |
1.42 |
1.70 |
1.76 |
2.56 |
| ATP | 1.15 |
1.11 |
.86 |
1.12 |
1.19 |
1.28 |
1.90 |
| KLA/ATP | 1.58 |
1.72 |
1.38 |
1.56 |
1.38 |
1.69 |
3.21 |
|
H2-K1 |  |
M69070 |
mRNA, complete cds. [M69070] |
KLA | 1.76 |
1.66 |
1.78 |
1.78 |
1.87 |
2.23 |
2.99 |
| ATP | .98 |
.97 |
1.19 |
1.45 |
1.36 |
1.68 |
2.17 |
| KLA/ATP | 1.68 |
1.70 |
1.87 |
1.96 |
1.87 |
2.13 |
3.82 |
|
H2-K1 |  |
NM_001001892 |
histocompatibility 2, K1, K region (H2-K1), transcript variant 1, mRNA [NM_001001892] |
KLA | 1.82 |
1.66 |
1.73 |
1.76 |
1.87 |
2.29 |
3.17 |
| ATP | .98 |
.97 |
1.13 |
1.32 |
1.29 |
1.57 |
2.09 |
| KLA/ATP | 1.64 |
1.71 |
1.77 |
1.82 |
1.71 |
2.12 |
3.91 |
|
H2-M1 |  |
NM_177636 |
histocompatibility 2, M region locus 1 (H2-M1), mRNA [NM_177636] |
KLA | .99 |
1.01 |
1.02 |
1.02 |
.97 |
1.03 |
1.04 |
| ATP | 1.01 |
.99 |
1.03 |
1.07 |
.92 |
1.03 |
.98 |
| KLA/ATP | 1.08 |
.97 |
.94 |
1.04 |
1.00 |
1.04 |
1.02 |
|
H2-M10.1
|  |
NM_013544 |
histocompatibility 2, M region locus 10.1 (H2-M10.1), mRNA [NM_013544] |
KLA | 1.04 |
1.00 |
1.05 |
.95 |
.98 |
1.04 |
.94 |
| ATP | 1.06 |
1.04 |
.96 |
.95 |
.97 |
.98 |
.98 |
| KLA/ATP | 1.02 |
1.07 |
.98 |
1.02 |
.92 |
.92 |
.99 |
|
H2-M10.2
|  |
NM_177923 |
histocompatibility 2, M region locus 10.2 (H2-M10.2), mRNA [NM_177923] |
KLA | 2.18 |
2.23 |
2.51 |
2.61 |
2.90 |
3.30 |
3.40 |
| ATP | 1.08 |
1.02 |
1.22 |
1.39 |
1.30 |
1.56 |
2.66 |
| KLA/ATP | 2.23 |
2.53 |
2.82 |
2.91 |
2.89 |
2.60 |
3.92 |
|
H2-M10.3
|  |
AY211080 |
major histocompatibility complex class Ib M10.3 mRNA, complete cds [AY211080] |
KLA | .95 |
1.08 |
.99 |
.95 |
1.00 |
1.11 |
1.04 |
| ATP | .98 |
.96 |
1.00 |
.99 |
1.00 |
.99 |
1.00 |
| KLA/ATP | 1.00 |
.99 |
1.00 |
1.00 |
.99 |
.96 |
1.03 |
|
H2-M10.4
|  |
NM_177634 |
histocompatibility 2, M region locus 10.4 (H2-M10.4), mRNA [NM_177634] |
KLA | 1.03 |
1.04 |
1.08 |
1.08 |
1.04 |
1.03 |
1.03 |
| ATP | 1.07 |
1.05 |
.97 |
1.08 |
.95 |
.97 |
1.02 |
| KLA/ATP | 1.02 |
.97 |
1.02 |
.99 |
.93 |
1.06 |
1.04 |
|
H2-M10.5
|  |
NM_177637 |
histocompatibility 2, M region locus 10.5 (H2-M10.5), mRNA [NM_177637] |
KLA | 1.00 |
1.04 |
1.13 |
.93 |
.99 |
1.00 |
1.07 |
| ATP | 1.02 |
1.02 |
1.04 |
.90 |
1.03 |
.99 |
.99 |
| KLA/ATP | 1.06 |
1.03 |
.97 |
1.03 |
1.03 |
.98 |
1.04 |
|
H2-M10.6
|  |
NM_201611 |
histocompatibility 2, M region locus 10.6 (H2-M10.6), mRNA [NM_201611] |
KLA | 1.06 |
.99 |
1.04 |
1.06 |
.98 |
1.03 |
.92 |
| ATP | 1.04 |
1.09 |
.96 |
.98 |
.94 |
1.07 |
.98 |
| KLA/ATP | 1.01 |
1.06 |
1.02 |
.96 |
.96 |
1.04 |
1.05 |
|
H2-M11 |  |
NM_177635 |
histocompatibility 2, M region locus 11 (H2-M11), mRNA [NM_177635] |
KLA | 1.03 |
1.07 |
1.06 |
1.02 |
.96 |
1.05 |
1.03 |
| ATP | 1.02 |
.96 |
1.08 |
.98 |
1.04 |
.94 |
.98 |
| KLA/ATP | 1.03 |
1.03 |
.99 |
1.01 |
1.01 |
.98 |
.99 |
|
H2-M3 |  |
NM_013819 |
histocompatibility 2, M region locus 3 (H2-M3), mRNA [NM_013819] |
KLA | 1.90 |
2.04 |
2.09 |
2.37 |
2.30 |
2.56 |
2.73 |
| ATP | 1.00 |
1.00 |
1.19 |
1.34 |
1.00 |
.70 |
1.09 |
| KLA/ATP | 1.77 |
1.94 |
2.37 |
2.49 |
1.89 |
1.67 |
2.06 |
|
H2-M9 |  |
NM_008205 |
histocompatibility 2, M region locus 9 (H2-M9), mRNA [NM_008205] |
KLA | 1.03 |
.99 |
.96 |
.98 |
1.01 |
.99 |
1.03 |
| ATP | .96 |
1.06 |
.94 |
.96 |
1.05 |
1.06 |
1.00 |
| KLA/ATP | .96 |
1.01 |
1.01 |
.99 |
.97 |
.95 |
.98 |
|
H2-Q1 |  |
NM_010390 |
histocompatibility 2, Q region locus 1 (H2-Q1), mRNA [NM_010390] |
KLA | 1.05 |
1.08 |
1.03 |
1.02 |
.98 |
1.09 |
1.00 |
| ATP | .99 |
.92 |
.93 |
1.01 |
1.01 |
1.04 |
1.00 |
| KLA/ATP | 1.07 |
1.00 |
1.00 |
.91 |
.97 |
1.07 |
1.04 |
|
H2-Q10 |  |
NM_010391 |
histocompatibility 2, Q region locus 10 (H2-Q10), mRNA [NM_010391] |
KLA | 1.50 |
1.50 |
1.70 |
1.64 |
1.67 |
1.79 |
2.18 |
| ATP | 1.12 |
1.11 |
1.09 |
1.46 |
1.42 |
1.43 |
1.69 |
| KLA/ATP | 1.61 |
1.72 |
1.79 |
1.94 |
1.81 |
1.81 |
2.93 |
|
H2-Q2 |  |
NM_010392 |
histocompatibility 2, Q region locus 2 (H2-Q2), mRNA [NM_010392] |
KLA | 1.55 |
1.52 |
1.61 |
1.45 |
1.83 |
1.94 |
2.47 |
| ATP | 1.09 |
1.13 |
.92 |
1.16 |
1.17 |
1.30 |
1.88 |
| KLA/ATP | 1.55 |
1.70 |
1.58 |
1.80 |
1.64 |
1.87 |
3.43 |
|
H2-Q7 |  |
NM_010394 |
histocompatibility 2, Q region locus 7 (H2-Q7), mRNA [NM_010394] |
KLA | 1.57 |
1.58 |
1.74 |
1.55 |
1.82 |
2.00 |
2.76 |
| ATP | 1.05 |
1.09 |
.84 |
1.12 |
1.12 |
1.23 |
2.00 |
| KLA/ATP | 1.63 |
1.75 |
1.43 |
1.67 |
1.53 |
1.80 |
3.48 |
|
H2-Q8 |  |
NM_023124 |
histocompatibility 2, Q region locus 8 (H2-Q8), mRNA [NM_023124] |
KLA | 7.48 |
6.46 |
6.41 |
7.15 |
7.46 |
9.60 |
18.27 |
| ATP | 1.01 |
.98 |
1.48 |
2.05 |
1.93 |
3.83 |
8.26 |
| KLA/ATP | 6.72 |
7.10 |
9.11 |
10.95 |
10.71 |
12.88 |
31.43 |
|
H2-T22 |  |
NM_010397 |
histocompatibility 2, T region locus 22 (H2-T22), mRNA [NM_010397] |
KLA | 5.21 |
5.40 |
5.81 |
6.31 |
7.42 |
9.49 |
7.50 |
| ATP | 1.01 |
.95 |
.88 |
.92 |
.93 |
3.65 |
5.53 |
| KLA/ATP | 4.83 |
5.12 |
4.58 |
4.74 |
4.81 |
6.89 |
14.89 |
|
H2-T23 |  |
NM_010398 |
histocompatibility 2, T region locus 23 (H2-T23), mRNA [NM_010398] |
KLA | 1.83 |
1.80 |
1.92 |
1.86 |
2.32 |
2.56 |
3.43 |
| ATP | 1.03 |
1.08 |
.85 |
1.18 |
1.09 |
1.30 |
2.49 |
| KLA/ATP | 1.76 |
1.92 |
1.62 |
1.93 |
1.76 |
2.13 |
4.06 |
|
H2-T24 |  |
NM_008207 |
histocompatibility 2, T region locus 24 (H2-T24), mRNA [NM_008207] |
KLA | 3.02 |
3.26 |
4.14 |
4.26 |
5.15 |
6.06 |
5.89 |
| ATP | 1.08 |
1.09 |
1.32 |
1.35 |
1.17 |
1.71 |
6.71 |
| KLA/ATP | 3.23 |
3.31 |
3.54 |
3.85 |
3.07 |
3.73 |
9.10 |
|
H2-T3 |  |
NM_008208 |
histocompatibility 2, T region locus 3 (H2-T3), mRNA [NM_008208] |
KLA | .95 |
1.04 |
1.00 |
.97 |
.97 |
.99 |
1.00 |
| ATP | .98 |
1.08 |
1.03 |
1.01 |
.98 |
1.02 |
1.03 |
| KLA/ATP | 1.05 |
.96 |
1.02 |
1.04 |
1.05 |
1.00 |
.97 |
|
H60a |  |
NM_010400 |
histocompatibility 60a (H60a), mRNA [NM_010400] |
KLA | 1.29 |
1.34 |
1.42 |
1.56 |
1.49 |
1.69 |
1.71 |
| ATP | 1.11 |
1.03 |
1.15 |
1.30 |
1.04 |
1.01 |
2.25 |
| KLA/ATP | 1.41 |
1.47 |
1.49 |
1.46 |
1.30 |
1.09 |
2.18 |
|
Hcst |  |
NM_011827 |
hematopoietic cell signal transducer (Hcst), mRNA [NM_011827] |
KLA | 1.04 |
1.08 |
1.17 |
1.24 |
1.05 |
.92 |
.88 |
| ATP | 1.10 |
1.00 |
1.17 |
1.57 |
1.29 |
1.08 |
1.22 |
| KLA/ATP | 1.17 |
1.27 |
1.33 |
1.59 |
1.39 |
1.03 |
1.36 |
|
Hras1 |  |
NM_008284 |
Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] |
KLA | .79 |
.82 |
.77 |
.82 |
.94 |
1.03 |
1.07 |
| ATP | 1.01 |
.95 |
.69 |
.83 |
.79 |
1.12 |
1.15 |
| KLA/ATP | .84 |
.77 |
.61 |
.65 |
.82 |
1.00 |
1.05 |
|
Icam1 |  |
BC008626 |
intercellular adhesion molecule, mRNA (cDNA clone MGC:6195 IMAGE:3588949), complete cds [BC008626] |
KLA | 36.67 |
32.93 |
28.63 |
27.91 |
14.65 |
8.16 |
4.15 |
| ATP | .96 |
.88 |
1.50 |
3.88 |
4.98 |
3.90 |
1.01 |
| KLA/ATP | 32.58 |
31.60 |
42.74 |
32.60 |
26.00 |
13.02 |
6.01 |
|
Icam1 |  |
NM_010493 |
intercellular adhesion molecule 1 (Icam1), mRNA [NM_010493] |
KLA | 15.66 |
15.20 |
12.96 |
12.31 |
9.39 |
6.17 |
3.81 |
| ATP | .96 |
1.06 |
1.21 |
4.19 |
4.33 |
3.16 |
1.06 |
| KLA/ATP | 14.31 |
15.46 |
17.84 |
17.60 |
13.77 |
8.36 |
5.42 |
|
Icam2 |  |
NM_010494 |
intercellular adhesion molecule 2 (Icam2), mRNA [NM_010494] |
KLA | .90 |
.84 |
.82 |
.72 |
.67 |
.61 |
.70 |
| ATP | 1.08 |
.96 |
1.28 |
1.48 |
2.29 |
1.22 |
.62 |
| KLA/ATP | .89 |
.89 |
1.11 |
1.00 |
1.32 |
1.23 |
.87 |
|
Ifna12 |  |
NM_177361 |
interferon alpha 12 (Ifna12), mRNA [NM_177361] |
KLA | 1.25 |
1.26 |
1.34 |
1.16 |
1.06 |
1.10 |
1.09 |
| ATP | 1.01 |
.97 |
1.07 |
1.09 |
1.17 |
1.20 |
1.07 |
| KLA/ATP | 1.12 |
1.29 |
1.72 |
1.54 |
1.59 |
1.56 |
1.05 |
|
Ifna13 |  |
NM_177347 |
interferon alpha 13 (Ifna13), mRNA [NM_177347] |
KLA | 1.32 |
1.27 |
1.26 |
1.34 |
1.15 |
1.24 |
1.20 |
| ATP | .95 |
1.08 |
1.29 |
1.79 |
1.41 |
1.22 |
1.08 |
| KLA/ATP | 1.36 |
1.35 |
2.04 |
2.81 |
2.07 |
1.44 |
1.19 |
|
Ifna2 |  |
K01411 |
gb|Mouse alpha-interferon (MuIFN-alpha), 3 cds & untranslated mRNA [K01411] |
KLA | 1.02 |
1.03 |
1.10 |
.96 |
.93 |
.99 |
1.01 |
| ATP | 1.02 |
.98 |
1.00 |
.98 |
1.02 |
.97 |
.95 |
| KLA/ATP | 1.02 |
1.04 |
1.18 |
1.08 |
1.13 |
1.04 |
1.01 |
|
Ifna2 |  |
NM_010503 |
interferon alpha 2 (Ifna2), mRNA [NM_010503] |
KLA | 1.08 |
1.06 |
1.07 |
1.06 |
.98 |
1.02 |
1.05 |
| ATP | .94 |
1.06 |
1.11 |
1.30 |
1.24 |
1.25 |
1.21 |
| KLA/ATP | 1.03 |
1.20 |
1.19 |
1.35 |
1.52 |
1.60 |
1.18 |
|
Ifna4 |  |
NM_010504 |
interferon alpha 4 (Ifna4), mRNA [NM_010504] |
KLA | .99 |
1.04 |
1.05 |
.97 |
1.00 |
.96 |
.99 |
| ATP | 1.01 |
.96 |
.98 |
1.01 |
1.00 |
1.00 |
.97 |
| KLA/ATP | 1.10 |
1.09 |
1.05 |
1.04 |
1.01 |
.97 |
1.01 |
|
Ifna5 |  |
NM_010505 |
interferon alpha 5 (Ifna5), mRNA [NM_010505] |
KLA | 1.15 |
1.23 |
1.51 |
1.26 |
1.03 |
1.06 |
1.05 |
| ATP | .99 |
.94 |
1.11 |
1.00 |
1.09 |
1.07 |
1.03 |
| KLA/ATP | 1.12 |
1.29 |
1.46 |
1.47 |
1.24 |
1.32 |
1.03 |
|
Ifna9 |  |
NM_010507 |
interferon alpha 9 (Ifna9), mRNA [NM_010507] |
KLA | 1.05 |
1.09 |
1.20 |
1.06 |
1.08 |
1.06 |
1.02 |
| ATP | .99 |
1.08 |
1.18 |
1.21 |
1.09 |
.99 |
.97 |
| KLA/ATP | 1.09 |
1.23 |
1.19 |
1.24 |
1.18 |
1.16 |
1.04 |
|
Ifnab |  |
BC116864 |
interferon alpha B, mRNA (cDNA clone MGC:151241 IMAGE:40126183), complete cds [BC116864] |
KLA | 1.20 |
1.33 |
1.29 |
1.30 |
1.20 |
1.20 |
1.08 |
| ATP | .99 |
.99 |
1.00 |
1.25 |
1.13 |
1.19 |
1.04 |
| KLA/ATP | 1.30 |
1.39 |
1.44 |
1.48 |
1.49 |
1.54 |
1.22 |
|
Ifnar1 |  |
NM_010508 |
interferon (alpha and beta) receptor 1 (Ifnar1), mRNA [NM_010508] |
KLA | 1.35 |
1.29 |
1.19 |
1.39 |
1.60 |
1.47 |
1.49 |
| ATP | 1.18 |
1.25 |
.94 |
1.06 |
1.07 |
1.48 |
1.52 |
| KLA/ATP | 1.56 |
1.57 |
.98 |
1.43 |
1.08 |
1.79 |
3.54 |
|
Ifnar2 |  |
NM_010509 |
interferon (alpha and beta) receptor 2 (Ifnar2), transcript variant 1, mRNA [NM_010509] |
KLA | 1.45 |
1.43 |
1.67 |
1.87 |
2.31 |
1.84 |
1.36 |
| ATP | .99 |
.92 |
.87 |
1.03 |
1.38 |
1.79 |
1.43 |
| KLA/ATP | 1.48 |
1.48 |
1.24 |
1.54 |
1.77 |
2.10 |
2.81 |
|
Ifnb1 |  |
NM_010510 |
interferon beta 1, fibroblast (Ifnb1), mRNA [NM_010510] |
KLA | 49.82 |
46.57 |
34.05 |
16.05 |
5.94 |
7.31 |
8.49 |
| ATP | .99 |
1.02 |
1.89 |
4.78 |
6.31 |
4.44 |
1.79 |
| KLA/ATP | 49.22 |
61.83 |
134.08 |
144.05 |
110.96 |
31.78 |
11.24 |
|
Ifng |  |
NM_008337 |
interferon gamma (Ifng), mRNA [NM_008337] |
KLA | 1.05 |
1.02 |
1.01 |
1.01 |
1.01 |
1.04 |
1.00 |
| ATP | 1.00 |
1.01 |
1.01 |
.98 |
.97 |
1.04 |
1.03 |
| KLA/ATP | 1.01 |
1.01 |
1.06 |
1.10 |
1.24 |
1.10 |
1.04 |
|
Ifngr1 |  |
NM_010511 |
interferon gamma receptor 1 (Ifngr1), mRNA [NM_010511] |
KLA | .81 |
.60 |
.37 |
.35 |
.34 |
.39 |
.54 |
| ATP | 1.05 |
.96 |
1.15 |
.97 |
.80 |
.67 |
.45 |
| KLA/ATP | .57 |
.57 |
.63 |
.36 |
.28 |
.33 |
.36 |
|
Ifngr2 |  |
NM_008338 |
interferon gamma receptor 2 (Ifngr2), mRNA [NM_008338] |
KLA | 1.45 |
1.49 |
1.74 |
2.22 |
3.22 |
2.42 |
1.96 |
| ATP | 1.11 |
1.03 |
.81 |
.78 |
1.12 |
1.28 |
1.34 |
| KLA/ATP | 1.48 |
1.41 |
1.17 |
1.23 |
1.48 |
1.89 |
2.13 |
|
Igh-VJ55 8 |  |
AY547436 |
immunoglobulin heavy chain VDJ region mRNA, partial cds [AY547436] |
KLA | 1.06 |
1.05 |
1.01 |
.93 |
1.03 |
.96 |
.93 |
| ATP | .99 |
1.00 |
1.06 |
.95 |
.96 |
1.06 |
1.05 |
| KLA/ATP | .98 |
.94 |
1.07 |
.95 |
.97 |
.99 |
1.02 |
|
Igh-VJ55 8 |  |
CA578712 |
gb|K0727F04-5N NIA Mouse Hematopoietic Stem Cell (Lin- [CA578712] |
KLA | .99 |
.94 |
1.01 |
1.10 |
.93 |
.97 |
.92 |
| ATP | .93 |
1.04 |
1.01 |
.98 |
1.05 |
.96 |
.95 |
| KLA/ATP | .99 |
.95 |
.95 |
.98 |
1.02 |
.98 |
.95 |
|
Igh-VJ55 8 |  |
ENSMUST00000103412 |
ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHA] [ENSMUST00000103412] |
KLA | 1.01 |
.97 |
1.20 |
1.01 |
.98 |
1.44 |
1.24 |
| ATP | .99 |
.98 |
1.07 |
1.03 |
1.00 |
1.01 |
1.21 |
| KLA/ATP | .99 |
1.02 |
.96 |
1.03 |
.97 |
1.13 |
1.30 |
|
Igh-VJ55 8 |  |
ENSMUST00000103413 |
ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHE] [ENSMUST00000103413] |
KLA | 1.00 |
.99 |
1.06 |
1.06 |
.99 |
1.03 |
1.02 |
| ATP | 1.08 |
1.06 |
1.06 |
1.06 |
1.02 |
1.06 |
.95 |
| KLA/ATP | 1.00 |
1.04 |
1.09 |
1.02 |
1.06 |
1.02 |
.95 |
|
Igh-VJ55 8 |  |
U39781 |
J558+ IgM heavy chain mRNA, hybridoma clone ME2B7, partial cds. [U39781] |
KLA | .93 |
.89 |
.98 |
.97 |
1.03 |
1.00 |
.94 |
| ATP | 1.04 |
1.02 |
1.08 |
.94 |
.93 |
.90 |
.79 |
| KLA/ATP | .88 |
.89 |
.97 |
.93 |
.88 |
.92 |
.82 |
|
Itgal |  |
AK156251 |
activated spleen cDNA, RIKEN full-length enriched library, clone:F830013L17 product:integrin alpha L, full insert sequence [AK156251] |
KLA | 5.36 |
5.78 |
4.86 |
5.55 |
7.02 |
8.63 |
11.12 |
| ATP | .99 |
1.17 |
1.22 |
1.57 |
1.35 |
1.95 |
3.79 |
| KLA/ATP | 5.42 |
5.89 |
4.95 |
5.91 |
3.96 |
4.93 |
10.15 |
|
Itgal |  |
NM_008400 |
integrin alpha L (Itgal), mRNA [NM_008400] |
KLA | 4.48 |
5.17 |
5.28 |
5.82 |
7.82 |
8.09 |
16.96 |
| ATP | 1.03 |
1.06 |
1.24 |
1.44 |
1.34 |
2.02 |
4.59 |
| KLA/ATP | 4.71 |
5.63 |
5.49 |
5.60 |
3.66 |
4.65 |
17.76 |
|
Itgb2 |  |
NM_008404 |
integrin beta 2 (Itgb2), mRNA [NM_008404] |
KLA | .78 |
.78 |
.97 |
.74 |
1.04 |
.94 |
1.14 |
| ATP | 1.24 |
1.23 |
.79 |
.95 |
1.12 |
.84 |
1.10 |
| KLA/ATP | .99 |
1.01 |
.60 |
.83 |
.78 |
.73 |
.99 |
|
Itgb2l |  |
NM_008405 |
integrin beta 2-like (Itgb2l), mRNA [NM_008405] |
KLA | .87 |
.98 |
.98 |
1.00 |
1.05 |
1.07 |
1.10 |
| ATP | 1.24 |
1.23 |
1.13 |
1.14 |
1.29 |
1.05 |
1.05 |
| KLA/ATP | 1.02 |
1.08 |
1.08 |
1.06 |
.98 |
.93 |
.95 |
|
Kir3dl1 |  |
NM_177749 |
killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1 (Kir3dl1), mRNA [NM_177749] |
KLA | 1.01 |
1.02 |
.98 |
1.01 |
1.03 |
1.01 |
1.03 |
| ATP | .99 |
.98 |
1.05 |
1.11 |
.95 |
1.05 |
1.04 |
| KLA/ATP | .98 |
1.02 |
.92 |
1.10 |
1.07 |
.98 |
1.00 |
|
Klra3 |  |
NM_010648 |
killer cell lectin-like receptor, subfamily A, member 3 (Klra3), mRNA [NM_010648] |
KLA | 1.02 |
1.00 |
.99 |
.98 |
.96 |
1.10 |
1.41 |
| ATP | 1.01 |
1.01 |
1.03 |
1.04 |
1.00 |
.94 |
1.13 |
| KLA/ATP | 1.02 |
1.00 |
.94 |
1.02 |
1.00 |
1.02 |
1.02 |
|
Klra7 |  |
NM_014194 |
killer cell lectin-like receptor, subfamily A, member 7 (Klra7), transcript variant 2, mRNA [NM_014194] |
KLA | 1.03 |
.96 |
.99 |
1.02 |
1.01 |
1.03 |
.99 |
| ATP | .99 |
.95 |
.95 |
1.00 |
1.09 |
1.05 |
1.09 |
| KLA/ATP | .94 |
.99 |
1.01 |
.99 |
1.02 |
1.06 |
1.08 |
|
Klra8 |  |
NM_010650 |
killer cell lectin-like receptor, subfamily A, member 8 (Klra8), mRNA [NM_010650] |
KLA | .95 |
.92 |
.94 |
1.02 |
.97 |
1.12 |
1.65 |
| ATP | 1.01 |
.98 |
1.11 |
1.05 |
.99 |
.99 |
1.22 |
| KLA/ATP | 1.02 |
1.03 |
.95 |
.97 |
.95 |
1.01 |
1.01 |
|
Klra9 |  |
NM_010651 |
killer cell lectin-like receptor subfamily A, member 9 (Klra9), mRNA [NM_010651] |
KLA | .96 |
.90 |
1.01 |
1.04 |
.95 |
1.08 |
1.68 |
| ATP | 1.02 |
1.05 |
1.07 |
1.09 |
.96 |
1.04 |
1.30 |
| KLA/ATP | 1.01 |
.98 |
1.00 |
1.03 |
.94 |
.99 |
1.07 |
|
Klrb1c |  |
NM_008527 |
killer cell lectin-like receptor subfamily B member 1C (Klrb1c), mRNA [NM_008527] |
KLA | .88 |
.88 |
.85 |
.89 |
.88 |
.90 |
.98 |
| ATP | 1.01 |
.96 |
1.03 |
.92 |
.87 |
.94 |
.93 |
| KLA/ATP | .87 |
.93 |
.86 |
.89 |
.87 |
.87 |
.85 |
|
Klrc1 |  |
NM_010652 |
killer cell lectin-like receptor subfamily C, member 1 (Klrc1), mRNA [NM_010652] |
KLA | 1.00 |
.96 |
.99 |
.98 |
1.00 |
.98 |
1.01 |
| ATP | 1.03 |
.97 |
1.01 |
.93 |
1.10 |
1.03 |
1.04 |
| KLA/ATP | .98 |
.99 |
.93 |
1.08 |
1.13 |
.99 |
1.03 |
|
Klrc2 |  |
AK036555 |
adult male bone cDNA, RIKEN full-length enriched library, clone:9830133D16 product:killer cell lectin-like receptor subfamily C, member 2, full insert sequence [AK036555] |
KLA | .98 |
1.00 |
1.01 |
1.02 |
1.09 |
.95 |
.95 |
| ATP | 1.07 |
1.04 |
.96 |
1.00 |
1.03 |
1.21 |
1.03 |
| KLA/ATP | 1.01 |
1.01 |
1.08 |
1.17 |
1.15 |
1.13 |
1.11 |
|
Klrc2 |  |
AK040721 |
adult male aorta and vein cDNA, RIKEN full-length enriched library, clone:A530020F15 product:killer cell lectin-like receptor subfamily C, member 2, full insert sequence. [AK040721] |
KLA | .93 |
.97 |
1.06 |
.98 |
.98 |
.98 |
1.04 |
| ATP | 1.03 |
1.03 |
1.01 |
1.00 |
1.00 |
.95 |
.94 |
| KLA/ATP | 1.01 |
1.07 |
.99 |
.96 |
1.00 |
.95 |
.98 |
|
Klrc3 |  |
NM_021378 |
killer cell lectin-like receptor subfamily C, member 3 (Klrc3), mRNA [NM_021378] |
KLA | .94 |
.98 |
1.00 |
1.05 |
.98 |
.99 |
.97 |
| ATP | .98 |
1.00 |
.98 |
1.03 |
1.07 |
1.00 |
.99 |
| KLA/ATP | .99 |
1.02 |
.98 |
.99 |
.95 |
.97 |
.98 |
|
Klrd1 |  |
NM_010654 |
killer cell lectin-like receptor, subfamily D, member 1 (Klrd1), mRNA [NM_010654] |
KLA | .98 |
.99 |
.99 |
.94 |
.94 |
.93 |
1.03 |
| ATP | 1.13 |
1.28 |
1.48 |
1.94 |
1.59 |
1.04 |
1.00 |
| KLA/ATP | 1.00 |
.95 |
1.04 |
1.20 |
1.09 |
1.00 |
.94 |
|
Klrk1 |  |
NM_033078 |
killer cell lectin-like receptor subfamily K, member 1 (Klrk1), transcript variant 1, mRNA [NM_033078] |
KLA | 2.39 |
2.96 |
3.81 |
3.16 |
2.96 |
1.97 |
1.34 |
| ATP | 1.12 |
1.05 |
1.13 |
1.17 |
1.06 |
1.14 |
1.08 |
| KLA/ATP | 2.56 |
2.79 |
2.32 |
2.12 |
1.68 |
1.43 |
1.15 |
|
Kras |  |
NM_021284 |
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] |
KLA | .53 |
.49 |
.40 |
.42 |
.49 |
.95 |
1.05 |
| ATP | .98 |
1.01 |
1.16 |
1.17 |
1.39 |
1.29 |
1.74 |
| KLA/ATP | .50 |
.47 |
.50 |
.56 |
1.00 |
1.24 |
1.58 |
|
LOC67670 8 |  |
XM_992322 |
ref|PREDICTED: Mus musculus similar to class I (Qa) Q2k antigen (LOC676708), mRNA [XM_992322] |
KLA | 2.18 |
2.22 |
2.32 |
2.27 |
2.28 |
2.77 |
3.62 |
| ATP | 1.04 |
1.17 |
1.17 |
2.19 |
1.83 |
1.75 |
2.30 |
| KLA/ATP | 2.20 |
2.44 |
2.25 |
3.41 |
2.30 |
2.63 |
5.00 |
|
Lat |  |
NM_010689 |
linker for activation of T cells (Lat), mRNA [NM_010689] |
KLA | .91 |
.95 |
.94 |
.87 |
.76 |
.63 |
.48 |
| ATP | .97 |
.99 |
1.01 |
1.50 |
1.59 |
1.49 |
1.00 |
| KLA/ATP | .91 |
1.04 |
.93 |
1.15 |
1.11 |
.96 |
.65 |
|
Lck |  |
NM_010693 |
lymphocyte protein tyrosine kinase (Lck), mRNA [NM_010693] |
KLA | 18.74 |
17.97 |
23.64 |
20.20 |
17.34 |
8.29 |
1.29 |
| ATP | 1.00 |
1.04 |
1.28 |
1.30 |
1.48 |
2.55 |
1.44 |
| KLA/ATP | 21.76 |
24.22 |
23.73 |
23.04 |
22.66 |
12.06 |
2.90 |
|
Lcp2 |  |
NM_010696 |
lymphocyte cytosolic protein 2 (Lcp2), mRNA [NM_010696] |
KLA | 9.10 |
9.37 |
9.29 |
7.53 |
9.33 |
5.54 |
4.23 |
| ATP | 1.25 |
1.38 |
.95 |
1.73 |
2.80 |
2.13 |
1.06 |
| KLA/ATP | 10.47 |
10.89 |
6.89 |
11.38 |
3.88 |
1.80 |
2.82 |
|
Map2k1 |  |
NM_008927 |
mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] |
KLA | 1.82 |
2.00 |
2.31 |
2.03 |
2.51 |
2.20 |
1.51 |
| ATP | .99 |
1.14 |
.81 |
.87 |
.90 |
1.57 |
1.11 |
| KLA/ATP | 1.90 |
2.03 |
1.50 |
1.93 |
1.63 |
2.03 |
2.06 |
|
Map2k2 |  |
NM_023138 |
mitogen-activated protein kinase kinase 2 (Map2k2), mRNA [NM_023138] |
KLA | .96 |
1.01 |
1.09 |
.99 |
1.11 |
1.15 |
1.42 |
| ATP | 1.07 |
1.05 |
.74 |
.86 |
1.04 |
1.16 |
1.21 |
| KLA/ATP | 1.14 |
1.03 |
.68 |
.78 |
.85 |
1.01 |
1.20 |
|
Mapk1 |  |
NM_001038663 |
mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] |
KLA | .97 |
1.03 |
.93 |
.86 |
.79 |
1.01 |
1.04 |
| ATP | .96 |
1.18 |
1.01 |
1.13 |
.84 |
1.04 |
1.16 |
| KLA/ATP | .99 |
.99 |
.84 |
.87 |
.63 |
.96 |
1.26 |
|
Mapk1 |  |
NM_011949 |
mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] |
KLA | .88 |
.80 |
.80 |
.73 |
.75 |
.76 |
.65 |
| ATP | .97 |
.96 |
1.06 |
.88 |
.90 |
.68 |
.48 |
| KLA/ATP | .82 |
.81 |
.78 |
.65 |
.64 |
.64 |
.45 |
|
Mapk3 |  |
NM_011952 |
mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] |
KLA | .81 |
.85 |
.88 |
.72 |
.79 |
.73 |
.90 |
| ATP | 1.13 |
1.30 |
.92 |
1.48 |
1.08 |
.68 |
1.03 |
| KLA/ATP | 1.01 |
1.01 |
.66 |
1.13 |
.77 |
.77 |
1.16 |
|
Mm.19506 1 |  |
76253707 |
Unknown |
KLA | 5.35 |
4.83 |
5.36 |
6.20 |
6.87 |
9.80 |
7.83 |
| ATP | .97 |
.90 |
.96 |
.77 |
.80 |
3.98 |
5.87 |
| KLA/ATP | 4.63 |
4.51 |
4.51 |
3.75 |
4.39 |
7.21 |
16.38 |
|
Mm.21312 8 |  |
141801344 |
Unknown |
KLA | .96 |
.95 |
.83 |
.77 |
.52 |
.99 |
1.32 |
| ATP | .80 |
.82 |
1.09 |
.80 |
.83 |
1.19 |
1.46 |
| KLA/ATP | .78 |
.92 |
.98 |
.62 |
.71 |
.94 |
1.41 |
|
Mm.22094 6 |  |
27545180 |
Unknown |
KLA | 1.00 |
.93 |
.97 |
1.05 |
1.06 |
1.29 |
1.13 |
| ATP | .90 |
.94 |
1.25 |
1.18 |
.85 |
.62 |
1.20 |
| KLA/ATP | .86 |
.99 |
1.14 |
.99 |
.83 |
.70 |
1.26 |
|
Mm.24936 4 |  |
133892283 |
Unknown |
KLA | 1.42 |
1.41 |
1.61 |
2.14 |
2.88 |
2.49 |
2.03 |
| ATP | .98 |
.98 |
.76 |
.77 |
1.09 |
1.23 |
1.28 |
| KLA/ATP | 1.32 |
1.32 |
1.07 |
1.12 |
1.38 |
1.85 |
1.95 |
|
Mm.25381 9 |  |
118130676 |
Unknown |
KLA | 1.81 |
1.88 |
1.96 |
1.62 |
1.89 |
2.44 |
1.56 |
| ATP | .92 |
.91 |
1.24 |
1.01 |
1.16 |
2.06 |
1.95 |
| KLA/ATP | 1.62 |
1.86 |
1.86 |
1.41 |
1.89 |
2.37 |
1.97 |
|
Mm.33138 9 |  |
158508469 |
Unknown |
KLA | .80 |
.79 |
.81 |
.82 |
.72 |
.64 |
.50 |
| ATP | .95 |
.85 |
.56 |
.48 |
.30 |
.33 |
.46 |
| KLA/ATP | .71 |
.64 |
.50 |
.41 |
.33 |
.32 |
.42 |
|
Mm.37708 7 |  |
158631169 |
Unknown |
KLA | .98 |
.98 |
1.06 |
1.06 |
.91 |
.97 |
1.04 |
| ATP | 1.00 |
1.07 |
1.01 |
1.06 |
1.09 |
.99 |
1.02 |
| KLA/ATP | 1.08 |
1.06 |
1.16 |
1.11 |
1.16 |
1.12 |
1.04 |
|
Mm.43967 5 |  |
133778954 |
Unknown |
KLA | 1.76 |
1.74 |
1.70 |
1.72 |
1.75 |
2.14 |
3.19 |
| ATP | 1.00 |
1.01 |
1.18 |
1.28 |
1.25 |
1.48 |
1.84 |
| KLA/ATP | 1.67 |
1.64 |
1.70 |
1.79 |
1.63 |
2.04 |
3.36 |
|
Mm.43967 5 |  |
149275074 |
Unknown |
KLA | 2.17 |
2.23 |
2.26 |
2.58 |
2.26 |
2.10 |
1.43 |
| ATP | .96 |
.91 |
1.12 |
.90 |
.70 |
1.10 |
1.47 |
| KLA/ATP | 1.96 |
2.10 |
1.92 |
1.51 |
1.12 |
1.35 |
1.99 |
|
Mm.43972 4 |  |
142350027 |
Unknown |
KLA | 1.01 |
.96 |
1.03 |
.97 |
1.03 |
.99 |
.95 |
| ATP | .98 |
1.02 |
.96 |
.96 |
1.07 |
.99 |
.98 |
| KLA/ATP | .98 |
1.03 |
1.00 |
1.02 |
1.00 |
.99 |
1.01 |
|
Mm.44089 1 |  |
118130823 |
Unknown |
KLA | 1.89 |
1.79 |
1.51 |
1.49 |
1.06 |
.68 |
.39 |
| ATP | .98 |
.94 |
1.11 |
1.07 |
.88 |
.68 |
.75 |
| KLA/ATP | 1.80 |
1.69 |
1.89 |
1.83 |
1.42 |
.79 |
.60 |
|
Mm.44165 1 |  |
160333403 |
Unknown |
KLA | 5.45 |
5.27 |
5.02 |
6.34 |
6.63 |
10.05 |
8.10 |
| ATP | .91 |
.84 |
.96 |
.75 |
.78 |
3.91 |
6.03 |
| KLA/ATP | 4.29 |
4.38 |
4.50 |
3.55 |
4.22 |
7.22 |
17.63 |
|
Mm.44244 2 |  |
148747422 |
Unknown |
KLA | 1.56 |
1.73 |
1.94 |
1.74 |
1.69 |
1.53 |
.87 |
| ATP | 1.02 |
1.11 |
1.14 |
1.34 |
1.32 |
1.32 |
1.08 |
| KLA/ATP | 1.74 |
1.94 |
1.86 |
1.90 |
1.69 |
1.95 |
2.43 |
|
Mm.44463
|  |
118129851 |
Unknown |
KLA | 1.01 |
.98 |
.97 |
1.02 |
.93 |
1.06 |
1.05 |
| ATP | .97 |
1.01 |
1.04 |
1.06 |
1.02 |
1.08 |
.97 |
| KLA/ATP | 1.02 |
1.06 |
.95 |
1.04 |
1.09 |
1.14 |
1.03 |
|
Mm.45800 4 |  |
6679616 |
Unknown |
KLA | 1.73 |
1.70 |
1.47 |
1.73 |
1.18 |
.65 |
.41 |
| ATP | .92 |
.91 |
1.06 |
1.06 |
1.03 |
.70 |
.69 |
| KLA/ATP | 1.79 |
1.66 |
2.07 |
1.51 |
1.37 |
.95 |
.70 |
|
Mm.57127
|  |
117168292 |
Unknown |
KLA | 1.20 |
1.25 |
1.28 |
1.18 |
1.14 |
1.13 |
1.12 |
| ATP | .98 |
.95 |
1.11 |
1.06 |
1.05 |
1.05 |
1.09 |
| KLA/ATP | 1.22 |
1.24 |
1.48 |
1.55 |
1.40 |
1.21 |
1.07 |
|
Ncr1 |  |
NM_010746 |
natural cytotoxicity triggering receptor 1 (Ncr1), mRNA [NM_010746] |
KLA | 1.00 |
.97 |
.98 |
.98 |
1.07 |
1.06 |
1.06 |
| ATP | 1.01 |
1.05 |
.90 |
1.00 |
1.04 |
1.05 |
.95 |
| KLA/ATP | 1.02 |
.99 |
.96 |
1.04 |
1.04 |
1.03 |
1.06 |
|
Nfat5 |  |
AK172011 |
activated spleen cDNA, RIKEN full-length enriched library, clone:F830029B05 product:nuclear factor of activated T-cells 5, full insert sequence. [AK172011] |
KLA | .94 |
.90 |
.93 |
.93 |
1.28 |
1.27 |
1.16 |
| ATP | .95 |
.76 |
1.13 |
1.27 |
1.93 |
2.21 |
1.18 |
| KLA/ATP | .85 |
.84 |
1.10 |
.92 |
1.53 |
1.63 |
1.66 |
|
Nfat5 |  |
NM_018823 |
nuclear factor of activated T-cells 5 (Nfat5), transcript variant b, mRNA [NM_018823] |
KLA | .95 |
1.01 |
.99 |
1.03 |
1.08 |
1.13 |
1.19 |
| ATP | 1.05 |
1.22 |
1.67 |
1.98 |
1.74 |
1.38 |
1.17 |
| KLA/ATP | 1.03 |
1.07 |
1.34 |
1.38 |
1.30 |
1.19 |
1.40 |
|
Nfat5 |  |
NM_133957 |
nuclear factor of activated T-cells 5 (Nfat5), transcript variant a, mRNA [NM_133957] |
KLA | 1.07 |
1.07 |
1.00 |
.96 |
1.42 |
1.36 |
1.51 |
| ATP | 1.15 |
1.19 |
1.81 |
4.36 |
6.34 |
3.49 |
1.12 |
| KLA/ATP | 1.27 |
1.08 |
1.87 |
2.72 |
3.58 |
3.05 |
2.07 |
|
Nfatc1 |  |
NM_016791 |
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (Nfatc1), transcript variant 1, mRNA [NM_016791] |
KLA | .71 |
.66 |
.68 |
.62 |
.63 |
.67 |
.81 |
| ATP | 1.12 |
1.29 |
1.15 |
1.21 |
.83 |
.63 |
1.25 |
| KLA/ATP | .78 |
.79 |
.65 |
.74 |
.59 |
.45 |
.92 |
|
Nfatc1 |  |
NM_198429 |
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (Nfatc1), transcript variant 2, mRNA [NM_198429] |
KLA | .49 |
.41 |
.50 |
.43 |
.50 |
.78 |
.69 |
| ATP | 1.05 |
.81 |
.84 |
.54 |
.60 |
.38 |
.69 |
| KLA/ATP | .46 |
.37 |
.45 |
.32 |
.62 |
.39 |
.61 |
|
Nfatc2 |  |
AK081853 |
16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130082H17 product:nuclear factor of activated T-cells, cytoplasmic 2, full insert sequence. [AK081853] |
KLA | .56 |
.52 |
.59 |
.61 |
.78 |
.78 |
.66 |
| ATP | 1.19 |
1.27 |
.67 |
.65 |
.62 |
.53 |
.79 |
| KLA/ATP | .52 |
.49 |
.71 |
.57 |
.65 |
.52 |
.53 |
|
Nfatc2 |  |
NM_001037177 |
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 (Nfatc2), transcript variant 2, mRNA [NM_001037177] |
KLA | .84 |
.79 |
.74 |
.82 |
.89 |
.98 |
.80 |
| ATP | 1.06 |
1.13 |
1.01 |
.87 |
.86 |
.83 |
1.10 |
| KLA/ATP | .76 |
.72 |
.89 |
.84 |
.84 |
.81 |
.84 |
|
Nfatc2 |  |
NM_010899 |
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 (Nfatc2), transcript variant 1, mRNA [NM_010899] |
KLA | .90 |
.91 |
.86 |
.91 |
.86 |
1.07 |
1.00 |
| ATP | 1.08 |
1.11 |
1.45 |
1.04 |
.88 |
.85 |
1.18 |
| KLA/ATP | .85 |
.89 |
.92 |
.89 |
.93 |
.84 |
1.13 |
|
Nfatc3 |  |
AK084848 |
13 days embryo lung cDNA, RIKEN full-length enriched library, clone:D430001G08 product:nuclear factor of activated T-cells, cytoplasmic 3, full insert sequence. [AK084848] |
KLA | 1.08 |
.96 |
.98 |
1.00 |
.98 |
1.03 |
.98 |
| ATP | 1.00 |
1.03 |
.93 |
.92 |
.92 |
1.11 |
.98 |
| KLA/ATP | 1.01 |
.87 |
1.10 |
.97 |
.96 |
.96 |
.99 |
|
Nfatc3 |  |
NM_010901 |
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (Nfatc3), mRNA [NM_010901] |
KLA | .77 |
.68 |
.67 |
.77 |
.85 |
.90 |
1.04 |
| ATP | 1.01 |
.95 |
.89 |
.70 |
.70 |
.92 |
.98 |
| KLA/ATP | .77 |
.66 |
.64 |
.59 |
.82 |
.90 |
.90 |
|
Nfatc4 |  |
AK014164 |
13 days embryo head cDNA, RIKEN full-length enriched library, clone:3110041H08 product:nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4, full insert sequence. [AK014164] |
KLA | .90 |
.92 |
.91 |
1.00 |
.99 |
.98 |
.95 |
| ATP | .90 |
1.03 |
.96 |
.98 |
.95 |
.97 |
1.00 |
| KLA/ATP | .95 |
.87 |
1.00 |
.98 |
.96 |
.96 |
.92 |
|
Nfatc4 |  |
NM_023699 |
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 (Nfatc4), mRNA [NM_023699] |
KLA | 1.28 |
1.38 |
1.44 |
1.58 |
1.40 |
1.41 |
1.46 |
| ATP | 1.03 |
1.06 |
1.23 |
1.24 |
1.32 |
1.40 |
1.41 |
| KLA/ATP | 1.30 |
1.38 |
1.47 |
1.28 |
1.38 |
1.40 |
1.63 |
|
Nras |  |
NM_010937 |
neuroblastoma ras oncogene (Nras), mRNA [NM_010937] |
KLA | 1.20 |
1.22 |
1.27 |
1.20 |
1.09 |
.91 |
.84 |
| ATP | .98 |
.91 |
.69 |
.61 |
.59 |
.67 |
.78 |
| KLA/ATP | 1.22 |
1.14 |
.97 |
.79 |
.73 |
.61 |
.72 |
|
Pak1 |  |
NM_011035 |
p21 (CDKN1A)-activated kinase 1 (Pak1), mRNA [NM_011035] |
KLA | .72 |
.77 |
.79 |
.71 |
.67 |
.73 |
.95 |
| ATP | 1.10 |
1.07 |
.99 |
1.15 |
1.27 |
.62 |
.51 |
| KLA/ATP | .85 |
.83 |
.73 |
.76 |
.76 |
.55 |
.33 |
|
Pik3ca |  |
ENSMUST00000108243 |
ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] |
KLA | 1.07 |
1.01 |
.91 |
.90 |
.98 |
.96 |
.86 |
| ATP | 1.03 |
.87 |
1.12 |
.63 |
1.22 |
1.86 |
.60 |
| KLA/ATP | 1.05 |
.82 |
.91 |
.61 |
1.17 |
1.26 |
.63 |
|
Pik3ca |  |
NM_008839 |
phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] |
KLA | 1.15 |
1.11 |
1.05 |
.82 |
.99 |
1.03 |
1.27 |
| ATP | .98 |
1.00 |
.79 |
.75 |
.96 |
1.32 |
1.10 |
| KLA/ATP | 1.10 |
.98 |
.64 |
.72 |
.80 |
1.20 |
1.41 |
|
Pik3cb |  |
NM_029094 |
phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] |
KLA | 1.06 |
1.06 |
1.03 |
.73 |
.68 |
.98 |
1.69 |
| ATP | 1.04 |
1.21 |
.95 |
1.02 |
.85 |
.93 |
1.73 |
| KLA/ATP | 1.15 |
1.27 |
.73 |
.83 |
.58 |
.81 |
1.81 |
|
Pik3cd |  |
NM_008840 |
phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] |
KLA | 2.28 |
2.42 |
3.10 |
4.17 |
3.35 |
2.31 |
1.34 |
| ATP | 1.02 |
.91 |
.99 |
.63 |
.30 |
.67 |
.80 |
| KLA/ATP | 2.14 |
2.23 |
2.70 |
1.51 |
1.17 |
.85 |
.72 |
|
Pik3cd |  |
U86587 |
phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] |
KLA | 2.21 |
2.24 |
3.71 |
3.17 |
3.67 |
2.66 |
1.48 |
| ATP | 1.00 |
1.03 |
.93 |
.96 |
.46 |
.75 |
.97 |
| KLA/ATP | 2.27 |
2.32 |
1.97 |
2.02 |
1.01 |
.99 |
.98 |
|
Pik3cg |  |
NM_020272 |
phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] |
KLA | .53 |
.53 |
.61 |
.64 |
.97 |
.86 |
.79 |
| ATP | 1.01 |
1.13 |
.88 |
.89 |
.52 |
.53 |
.53 |
| KLA/ATP | .58 |
.53 |
.43 |
.60 |
.40 |
.43 |
.62 |
|
Pik3r1 |  |
NM_001077495 |
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] |
KLA | 1.05 |
1.07 |
1.03 |
1.00 |
1.01 |
1.20 |
.85 |
| ATP | .97 |
1.02 |
1.48 |
1.42 |
1.76 |
1.33 |
1.23 |
| KLA/ATP | 1.11 |
1.12 |
1.06 |
1.17 |
1.24 |
.99 |
1.12 |
|
Pik3r2 |  |
NM_008841 |
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] |
KLA | .50 |
.50 |
.48 |
.43 |
.46 |
.66 |
.75 |
| ATP | .78 |
.68 |
.45 |
.43 |
.28 |
.57 |
1.37 |
| KLA/ATP | .49 |
.38 |
.32 |
.33 |
.38 |
.67 |
1.10 |
|
Pik3r3 |  |
NM_181585 |
phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] |
KLA | 1.59 |
1.49 |
1.37 |
1.17 |
1.05 |
1.55 |
1.41 |
| ATP | 1.12 |
1.00 |
1.33 |
1.70 |
2.01 |
2.37 |
2.02 |
| KLA/ATP | 1.63 |
1.54 |
1.58 |
1.70 |
2.43 |
2.68 |
1.92 |
|
Pik3r5 |  |
NM_177320 |
phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] |
KLA | 3.57 |
3.58 |
4.16 |
3.54 |
4.11 |
2.59 |
2.39 |
| ATP | 1.08 |
1.08 |
.93 |
1.67 |
3.11 |
1.88 |
1.34 |
| KLA/ATP | 3.91 |
3.70 |
3.30 |
3.80 |
2.70 |
2.04 |
3.00 |
|
Plcg2 |  |
NM_172285 |
phospholipase C, gamma 2 (Plcg2), mRNA [NM_172285] |
KLA | .76 |
.74 |
.68 |
.66 |
.71 |
.92 |
.95 |
| ATP | .96 |
.90 |
.95 |
.87 |
.81 |
.79 |
.91 |
| KLA/ATP | .76 |
.71 |
.69 |
.62 |
.72 |
.78 |
.68 |
|
Ppp3ca |  |
NM_008913 |
protein phosphatase 3, catalytic subunit, alpha isoform (Ppp3ca), mRNA [NM_008913] |
KLA | .76 |
.85 |
.81 |
.85 |
.73 |
.70 |
.52 |
| ATP | .96 |
.78 |
.55 |
.46 |
.31 |
.33 |
.48 |
| KLA/ATP | .74 |
.64 |
.52 |
.42 |
.37 |
.36 |
.45 |
|
Ppp3cb |  |
AK135203 |
12 days embryo male wolffian duct includes surrounding region cDNA, RIKEN full-length enriched library, clone:6720421K10 product:protein phosphatase 3, catalytic subunit, beta isoform, full insert sequence. [AK135203] |
KLA | 1.74 |
1.57 |
1.91 |
1.59 |
1.47 |
1.26 |
1.40 |
| ATP | 1.17 |
1.03 |
1.30 |
1.00 |
.81 |
.62 |
1.37 |
| KLA/ATP | 1.68 |
1.70 |
1.91 |
1.37 |
1.09 |
.47 |
1.13 |
|
Ppp3cb |  |
AK171904 |
activated spleen cDNA, RIKEN full-length enriched library, clone:F830018L06 product:Protein phosphatase 3 catalytic subunit beta3 (EC 3.1.3.16) (Serine [AK171904] |
KLA | 1.29 |
1.29 |
1.21 |
1.15 |
1.22 |
1.13 |
1.28 |
| ATP | .90 |
.86 |
.80 |
.98 |
.94 |
.73 |
.92 |
| KLA/ATP | 1.06 |
1.03 |
.77 |
1.04 |
.92 |
.68 |
.90 |
|
Ppp3cb |  |
NM_008914 |
protein phosphatase 3, catalytic subunit, beta isoform (Ppp3cb), mRNA [NM_008914] |
KLA | 1.21 |
1.29 |
1.38 |
1.24 |
1.29 |
1.08 |
1.23 |
| ATP | 1.15 |
1.31 |
1.09 |
1.29 |
.86 |
.60 |
.64 |
| KLA/ATP | 1.33 |
1.40 |
1.04 |
1.28 |
.79 |
.58 |
.73 |
|
Ppp3cc |  |
AK037563 |
16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130026K22 product:unclassifiable, full insert sequence [AK037563] |
KLA | 1.27 |
1.18 |
1.21 |
1.15 |
1.01 |
.92 |
1.36 |
| ATP | .96 |
1.09 |
1.10 |
1.03 |
.85 |
1.06 |
1.47 |
| KLA/ATP | 1.17 |
1.24 |
1.07 |
1.13 |
.91 |
.88 |
1.36 |
|
Ppp3cc |  |
NM_008915 |
protein phosphatase 3, catalytic subunit, gamma isoform (Ppp3cc), mRNA [NM_008915] |
KLA | 1.64 |
1.81 |
1.79 |
1.35 |
.90 |
.70 |
1.31 |
| ATP | .90 |
.90 |
1.13 |
.93 |
.86 |
1.40 |
1.60 |
| KLA/ATP | 1.45 |
1.62 |
1.74 |
1.47 |
1.04 |
1.01 |
1.31 |
|
Ppp3r1 |  |
NM_024459 |
protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type I) (Ppp3r1), mRNA [NM_024459] |
KLA | 1.02 |
1.17 |
.93 |
1.27 |
1.15 |
1.30 |
1.30 |
| ATP | .97 |
.95 |
.77 |
.91 |
.99 |
1.18 |
1.10 |
| KLA/ATP | 1.12 |
1.04 |
.88 |
1.00 |
1.10 |
1.10 |
1.07 |
|
Ppp3r2 |  |
NM_001004025 |
protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type II) (Ppp3r2), mRNA [NM_001004025] |
KLA | 1.03 |
1.05 |
1.06 |
1.08 |
1.12 |
1.05 |
1.04 |
| ATP | 1.00 |
1.02 |
1.04 |
1.04 |
.99 |
.99 |
1.01 |
| KLA/ATP | 1.04 |
1.12 |
1.03 |
1.09 |
1.00 |
.99 |
1.00 |
|
Prf1 |  |
NM_011073 |
perforin 1 (pore forming protein) (Prf1), mRNA [NM_011073] |
KLA | .99 |
1.02 |
1.05 |
1.08 |
1.00 |
1.03 |
.98 |
| ATP | 1.00 |
.97 |
1.03 |
.97 |
.97 |
.98 |
.91 |
| KLA/ATP | 1.07 |
.99 |
.93 |
.98 |
.98 |
.95 |
.99 |
|
Prkca |  |
NM_011101 |
protein kinase C, alpha (Prkca), mRNA [NM_011101] |
KLA | 1.00 |
.96 |
.94 |
.95 |
.95 |
.89 |
.96 |
| ATP | 1.00 |
1.03 |
.91 |
.94 |
.82 |
.87 |
1.13 |
| KLA/ATP | 1.02 |
.95 |
.91 |
.86 |
.78 |
.84 |
.94 |
|
Prkcb1 |  |
NM_008855 |
protein kinase C, beta 1 (Prkcb1), mRNA [NM_008855] |
KLA | .92 |
.95 |
.93 |
.78 |
.77 |
1.08 |
1.83 |
| ATP | 1.03 |
1.12 |
1.09 |
1.23 |
.90 |
2.08 |
.96 |
| KLA/ATP | .98 |
.99 |
.82 |
.89 |
.62 |
1.01 |
1.08 |
|
Prkcc |  |
NM_011102 |
protein kinase C, gamma (Prkcc), mRNA [NM_011102] |
KLA | 1.02 |
1.04 |
1.11 |
1.04 |
.96 |
1.02 |
1.05 |
| ATP | .98 |
.98 |
1.05 |
1.03 |
1.08 |
.96 |
.95 |
| KLA/ATP | 1.21 |
1.16 |
1.09 |
1.07 |
1.04 |
.98 |
.93 |
|
Ptk2b |  |
NM_172498 |
PTK2 protein tyrosine kinase 2 beta (Ptk2b), mRNA [NM_172498] |
KLA | 1.34 |
1.39 |
1.78 |
1.70 |
2.36 |
2.26 |
1.77 |
| ATP | 1.08 |
1.21 |
.59 |
.69 |
.65 |
.71 |
1.17 |
| KLA/ATP | 1.41 |
1.55 |
1.07 |
1.33 |
1.07 |
1.24 |
1.80 |
|
Ptpn11 |  |
NM_001109992 |
protein tyrosine phosphatase, non-receptor type 11 (Ptpn11), transcript variant 2, mRNA [NM_001109992] |
KLA | 1.52 |
1.71 |
1.59 |
1.78 |
1.62 |
1.57 |
1.35 |
| ATP | 1.04 |
.93 |
.86 |
.79 |
1.09 |
1.95 |
1.90 |
| KLA/ATP | 1.59 |
1.61 |
1.45 |
1.11 |
1.18 |
1.82 |
3.02 |
|
Ptpn11 |  |
NM_011202 |
protein tyrosine phosphatase, non-receptor type 11 (Ptpn11), transcript variant 1, mRNA [NM_011202] |
KLA | 1.32 |
1.28 |
1.17 |
1.21 |
1.18 |
1.06 |
1.05 |
| ATP | .97 |
.77 |
.71 |
.56 |
.90 |
1.27 |
1.04 |
| KLA/ATP | 1.22 |
1.21 |
1.02 |
.70 |
.96 |
1.06 |
.94 |
|
Ptpn6 |  |
NM_001077705 |
protein tyrosine phosphatase, non-receptor type 6 (Ptpn6), transcript variant 2, mRNA [NM_001077705] |
KLA | .87 |
.90 |
1.03 |
1.05 |
1.83 |
1.96 |
2.34 |
| ATP | 1.06 |
1.09 |
.94 |
1.08 |
.51 |
.34 |
1.04 |
| KLA/ATP | .98 |
.93 |
.71 |
.95 |
.67 |
.64 |
1.44 |
|
Ptpn6 |  |
NM_013545 |
protein tyrosine phosphatase, non-receptor type 6 (Ptpn6), transcript variant 1, mRNA [NM_013545] |
KLA | 1.24 |
1.20 |
1.46 |
1.42 |
2.43 |
2.27 |
2.10 |
| ATP | 1.18 |
1.20 |
1.10 |
1.49 |
.80 |
.58 |
1.09 |
| KLA/ATP | 1.36 |
1.42 |
1.27 |
1.66 |
1.12 |
.87 |
1.46 |
|
Ptpn6 |  |
S63763 |
gb|me/Hcph (mev)=viable motheaten/hematopoietic cell protein-tyrosine phosphatase {insertion} [mice, mRNA Partial Mutant, 120 nt]. [S63763] |
KLA | 1.06 |
1.03 |
1.12 |
1.14 |
1.11 |
1.01 |
1.09 |
| ATP | 1.03 |
.97 |
.96 |
.90 |
.89 |
1.17 |
1.76 |
| KLA/ATP | 1.07 |
1.00 |
1.03 |
.98 |
1.00 |
1.29 |
1.44 |
|
Rac1 |  |
NM_009007 |
RAS-related C3 botulinum substrate 1 (Rac1), mRNA [NM_009007] |
KLA | 1.02 |
1.01 |
1.02 |
.99 |
1.03 |
1.15 |
1.08 |
| ATP | .99 |
1.15 |
1.01 |
1.27 |
1.06 |
1.20 |
1.06 |
| KLA/ATP | 1.00 |
1.04 |
.88 |
1.16 |
.91 |
1.21 |
1.38 |
|
Rac2 |  |
NM_009008 |
RAS-related C3 botulinum substrate 2 (Rac2), mRNA [NM_009008] |
KLA | 1.55 |
1.68 |
1.86 |
2.15 |
3.36 |
3.59 |
3.74 |
| ATP | 1.13 |
1.16 |
.74 |
.99 |
.84 |
.91 |
1.66 |
| KLA/ATP | 1.59 |
1.71 |
1.19 |
1.56 |
1.21 |
1.60 |
3.48 |
|
Rac3 |  |
NM_133223 |
RAS-related C3 botulinum substrate 3 (Rac3), mRNA [NM_133223] |
KLA | 2.03 |
2.20 |
2.64 |
2.18 |
2.95 |
2.29 |
1.41 |
| ATP | 1.02 |
1.12 |
.94 |
1.42 |
1.16 |
.84 |
.87 |
| KLA/ATP | 2.30 |
2.32 |
1.57 |
2.55 |
1.75 |
1.47 |
1.61 |
|
Raet1a |  |
NM_009016 |
retinoic acid early transcript 1, alpha (Raet1a), mRNA [NM_009016] |
KLA | 1.76 |
1.82 |
1.73 |
1.48 |
1.32 |
.96 |
.56 |
| ATP | .99 |
1.02 |
1.05 |
1.27 |
1.00 |
.77 |
.91 |
| KLA/ATP | 1.76 |
1.82 |
1.61 |
1.90 |
1.35 |
.97 |
1.03 |
|
Raet1e |  |
NM_198193 |
retinoic acid early transcript 1E (Raet1e), mRNA [NM_198193] |
KLA | 1.83 |
1.92 |
1.73 |
1.45 |
1.17 |
.69 |
.56 |
| ATP | .93 |
1.00 |
.97 |
1.10 |
.83 |
.72 |
1.14 |
| KLA/ATP | 1.90 |
1.72 |
1.43 |
1.77 |
1.16 |
.78 |
.80 |
|
Raf1 |  |
AK036317 |
16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] |
KLA | 1.47 |
1.34 |
1.55 |
1.29 |
1.59 |
1.32 |
1.46 |
| ATP | 1.05 |
.98 |
.54 |
.63 |
3.32 |
2.07 |
1.01 |
| KLA/ATP | 1.57 |
1.33 |
.79 |
.96 |
2.26 |
1.38 |
1.35 |
|
Raf1 |  |
NM_029780 |
v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] |
KLA | 1.65 |
1.64 |
1.93 |
1.77 |
1.77 |
1.72 |
1.81 |
| ATP | .95 |
.96 |
.83 |
.80 |
2.22 |
2.92 |
1.19 |
| KLA/ATP | 1.68 |
1.64 |
1.39 |
1.32 |
1.85 |
2.50 |
2.06 |
|
Sh2d1a |  |
AK042476 |
3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630095D20 product:SH2 domain protein 1A, full insert sequence. [AK042476] |
KLA | .93 |
.99 |
1.01 |
.99 |
.98 |
1.02 |
1.02 |
| ATP | .99 |
.96 |
.96 |
.99 |
1.08 |
1.01 |
.98 |
| KLA/ATP | .97 |
1.07 |
1.03 |
1.05 |
.94 |
.94 |
.95 |
|
Sh2d1a |  |
NM_011364 |
SH2 domain protein 1A (Sh2d1a), mRNA [NM_011364] |
KLA | 1.04 |
.97 |
1.00 |
1.02 |
.98 |
.99 |
1.00 |
| ATP | .95 |
.98 |
.97 |
1.01 |
.99 |
1.05 |
1.03 |
| KLA/ATP | .99 |
1.04 |
1.01 |
.97 |
1.05 |
.99 |
1.02 |
|
Sh2d1b1 |  |
AK089191 |
NOD-derived CD11c +ve dendritic cells cDNA, RIKEN full-length enriched library, clone:F630034C03 product:EWS [AK089191] |
KLA | .87 |
.82 |
.81 |
.83 |
.78 |
.88 |
1.01 |
| ATP | 1.06 |
1.02 |
.94 |
.95 |
.87 |
.84 |
.89 |
| KLA/ATP | .87 |
.80 |
.83 |
.84 |
.81 |
.79 |
.87 |
|
Sh2d1b1 |  |
NM_012009 |
SH2 domain protein 1B1 (Sh2d1b1), mRNA [NM_012009] |
KLA | .50 |
.48 |
.47 |
.57 |
.58 |
.72 |
1.19 |
| ATP | 1.08 |
.97 |
1.04 |
.90 |
.66 |
.75 |
.79 |
| KLA/ATP | .46 |
.46 |
.53 |
.61 |
.64 |
1.11 |
1.48 |
|
Sh3bp2 |  |
NM_011893 |
SH3-domain binding protein 2 (Sh3bp2), mRNA [NM_011893] |
KLA | 1.07 |
1.15 |
1.84 |
1.48 |
1.84 |
1.96 |
1.57 |
| ATP | 1.00 |
1.12 |
.78 |
.45 |
.76 |
.88 |
1.31 |
| KLA/ATP | 1.28 |
1.21 |
1.18 |
.83 |
1.44 |
1.19 |
1.89 |
|
Shc1 |  |
NM_011368 |
src homology 2 domain-containing transforming protein C1 (Shc1), transcript variant 2, mRNA [NM_011368] |
KLA | .88 |
.87 |
.86 |
.83 |
1.09 |
1.11 |
1.12 |
| ATP | 1.04 |
1.25 |
.85 |
1.17 |
.93 |
1.16 |
1.00 |
| KLA/ATP | .93 |
.96 |
.62 |
.96 |
.75 |
1.25 |
1.19 |
|
Shc2 |  |
NM_001024539 |
src homology 2 domain-containing transforming protein C2 (Shc2), mRNA [NM_001024539] |
KLA | 1.19 |
1.25 |
1.22 |
1.16 |
1.15 |
1.14 |
.98 |
| ATP | 1.04 |
1.14 |
1.15 |
1.53 |
1.29 |
1.06 |
1.09 |
| KLA/ATP | 1.26 |
1.24 |
1.26 |
1.49 |
1.31 |
1.30 |
1.30 |
|
Shc3 |  |
NM_009167 |
src homology 2 domain-containing transforming protein C3 (Shc3), mRNA [NM_009167] |
KLA | 1.00 |
.98 |
1.06 |
1.06 |
1.12 |
1.08 |
1.04 |
| ATP | .99 |
1.02 |
1.00 |
1.05 |
1.00 |
1.08 |
1.08 |
| KLA/ATP | 1.08 |
1.06 |
1.01 |
1.06 |
1.03 |
1.12 |
1.41 |
|
Shc4 |  |
NM_199022 |
SHC (Src homology 2 domain containing) family, member 4 (Shc4), mRNA [NM_199022] |
KLA | 1.03 |
1.03 |
1.01 |
1.06 |
1.09 |
1.03 |
1.06 |
| ATP | .99 |
1.00 |
1.03 |
1.02 |
1.04 |
1.04 |
1.01 |
| KLA/ATP | .98 |
.97 |
1.06 |
1.05 |
1.00 |
1.00 |
1.14 |
|
Sos1 |  |
NM_009231 |
Son of sevenless homolog 1 (Drosophila) (Sos1), mRNA [NM_009231] |
KLA | 2.36 |
2.40 |
3.42 |
3.15 |
2.78 |
1.81 |
1.71 |
| ATP | .99 |
1.00 |
.99 |
1.15 |
1.14 |
1.25 |
1.24 |
| KLA/ATP | 2.41 |
2.26 |
1.95 |
2.44 |
1.47 |
1.66 |
1.37 |
|
Sos2 |  |
XM_127051 |
gb|PREDICTED: Mus musculus Son of sevenless homolog 2 (Drosophila) (Sos2), mRNA [XM_127051] |
KLA | .81 |
.77 |
.79 |
.92 |
1.04 |
1.06 |
1.20 |
| ATP | 1.00 |
1.00 |
1.09 |
.79 |
.68 |
.81 |
.94 |
| KLA/ATP | .77 |
.69 |
.71 |
.60 |
.64 |
.77 |
1.07 |
|
Syk |  |
NM_011518 |
spleen tyrosine kinase (Syk), mRNA [NM_011518] |
KLA | 2.48 |
2.59 |
2.57 |
2.26 |
3.29 |
3.75 |
3.19 |
| ATP | .96 |
.85 |
.59 |
1.01 |
2.80 |
3.77 |
2.11 |
| KLA/ATP | 2.56 |
2.09 |
1.16 |
1.35 |
2.50 |
4.33 |
5.10 |
|
Tnf |  |
NM_013693 |
tumor necrosis factor (Tnf), mRNA [NM_013693] |
KLA | 13.35 |
12.76 |
10.71 |
9.03 |
10.64 |
7.39 |
8.32 |
| ATP | 2.01 |
2.48 |
8.27 |
19.20 |
9.72 |
4.09 |
1.49 |
| KLA/ATP | 12.72 |
15.76 |
12.73 |
17.34 |
5.10 |
3.61 |
6.07 |
|
Tnfrsf10 b |  |
NM_020275 |
tumor necrosis factor receptor superfamily, member 10b (Tnfrsf10b), mRNA [NM_020275] |
KLA | 1.29 |
1.24 |
1.23 |
1.14 |
.96 |
.88 |
.87 |
| ATP | .99 |
1.04 |
1.06 |
1.14 |
.95 |
1.10 |
1.15 |
| KLA/ATP | 1.26 |
1.26 |
1.21 |
1.23 |
1.03 |
.93 |
.93 |
|
Tnfsf10 |  |
NM_009425 |
tumor necrosis factor (ligand) superfamily, member 10 (Tnfsf10), mRNA [NM_009425] |
KLA | 31.48 |
31.73 |
32.62 |
36.94 |
28.34 |
23.40 |
4.96 |
| ATP | 1.06 |
.93 |
1.28 |
1.24 |
1.07 |
2.74 |
3.33 |
| KLA/ATP | 28.07 |
30.23 |
43.53 |
33.98 |
27.97 |
18.71 |
17.43 |
|
Tyrobp |  |
NM_011662 |
TYRO protein tyrosine kinase binding protein (Tyrobp), mRNA [NM_011662] |
KLA | .80 |
.78 |
.84 |
.69 |
.72 |
.69 |
.92 |
| ATP | 1.10 |
1.12 |
.90 |
1.11 |
.83 |
.71 |
.90 |
| KLA/ATP | .92 |
.90 |
.64 |
.87 |
.65 |
.61 |
.92 |
|
Ulbp1 |  |
AK085119 |
13 days embryo lung cDNA, RIKEN full-length enriched library, clone:D430040B02 product:A430108B07RIK PROTEIN homolog [Mus musculus], full insert sequence [AK085119] |
KLA | 1.71 |
1.73 |
1.52 |
1.01 |
.69 |
.76 |
.42 |
| ATP | .97 |
1.03 |
1.30 |
1.02 |
1.42 |
1.69 |
.44 |
| KLA/ATP | 1.76 |
1.93 |
1.94 |
1.67 |
2.09 |
2.60 |
1.78 |
|
Vav1 |  |
NM_011691 |
vav 1 oncogene (Vav1), mRNA [NM_011691] |
KLA | .79 |
.83 |
.98 |
1.17 |
1.97 |
2.42 |
2.26 |
| ATP | 1.06 |
1.02 |
.88 |
1.01 |
1.34 |
.82 |
1.36 |
| KLA/ATP | .88 |
.85 |
.73 |
.78 |
1.25 |
1.47 |
2.17 |
|
Vav2 |  |
BC053060 |
vav 2 oncogene, mRNA (cDNA clone MGC:62363 IMAGE:5704852), complete cds [BC053060] |
KLA | .73 |
.58 |
.55 |
1.16 |
.76 |
1.35 |
1.75 |
| ATP | .99 |
.89 |
.79 |
.82 |
.67 |
.85 |
1.09 |
| KLA/ATP | .64 |
.63 |
.61 |
.65 |
.66 |
.80 |
1.23 |
|
Vav2 |  |
NM_009500 |
vav 2 oncogene (Vav2), mRNA [NM_009500] |
KLA | .98 |
1.05 |
.98 |
.99 |
1.02 |
1.36 |
1.43 |
| ATP | 1.07 |
1.06 |
.96 |
1.01 |
.89 |
.95 |
1.08 |
| KLA/ATP | 1.04 |
1.05 |
.98 |
1.03 |
.88 |
.99 |
1.13 |
|
Vav3 |  |
NM_020505 |
vav 3 oncogene (Vav3), transcript variant 1, mRNA [NM_020505] |
KLA | .95 |
.94 |
.86 |
.87 |
.82 |
.66 |
.56 |
| ATP | 1.06 |
1.09 |
.81 |
1.05 |
.80 |
.75 |
.85 |
| KLA/ATP | 1.00 |
.84 |
.62 |
.85 |
.74 |
.56 |
.74 |
|
Zap70 |  |
NM_009539 |
zeta-chain (TCR) associated protein kinase (Zap70), mRNA [NM_009539] |
KLA | .94 |
.88 |
.84 |
.86 |
1.01 |
.92 |
.94 |
| ATP | 1.02 |
.99 |
.87 |
.87 |
1.58 |
.98 |
.96 |
| KLA/ATP | .94 |
.82 |
.83 |
.77 |
1.09 |
.93 |
1.02 |
|